Your browser doesn't support javascript.
loading
TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
de Kouchkovsky, Ivan; Zhang, Li; Philip, Errol J; Wright, Francis; Kim, Daniel M; Natesan, Divya; Kwon, Daniel; Ho, Hansen; Ho, Son; Chan, Emily; Porten, Sima P; Wong, Anthony C; Desai, Arpita; Huang, Franklin W; Chou, Jonathan; Oh, David Y; Pruthi, Raj S; Fong, Lawrence; Small, Eric J; Friedlander, Terence W; Koshkin, Vadim S.
Affiliation
  • de Kouchkovsky I; Medicine, University of California San Francisco, San Francisco, California, USA.
  • Zhang L; Medicine, University of California San Francisco, San Francisco, California, USA.
  • Philip EJ; University of California San Francisco School of Medicine, San Francisco, California, USA.
  • Wright F; University of California San Francisco School of Medicine, San Francisco, California, USA.
  • Kim DM; University of California San Francisco School of Medicine, San Francisco, California, USA.
  • Natesan D; Medicine, University of California San Francisco, San Francisco, California, USA.
  • Kwon D; Medicine, University of California San Francisco, San Francisco, California, USA.
  • Ho H; University of California San Francisco School of Pharmacy, San Francisco, California, USA.
  • Ho S; University of California San Francisco School of Pharmacy, San Francisco, California, USA.
  • Chan E; Pathology, University of California San Francisco, San Francisco, California, USA.
  • Porten SP; Urology, University of California San Francisco, San Francisco, California, USA.
  • Wong AC; Radiation Oncology, University of California San Francisco, San Francisco, California, USA.
  • Desai A; Medicine, University of California San Francisco, San Francisco, California, USA.
  • Huang FW; Medicine, University of California San Francisco, San Francisco, California, USA.
  • Chou J; Medicine, University of California San Francisco, San Francisco, California, USA.
  • Oh DY; Medicine, University of California San Francisco, San Francisco, California, USA.
  • Pruthi RS; Urology, University of California San Francisco, San Francisco, California, USA.
  • Fong L; Medicine, University of California San Francisco, San Francisco, California, USA.
  • Small EJ; Medicine, University of California San Francisco, San Francisco, California, USA.
  • Friedlander TW; Medicine, University of California San Francisco, San Francisco, California, USA.
  • Koshkin VS; Medicine, University of California San Francisco, San Francisco, California, USA Vadim.Koshkin@ucsf.edu.
J Immunother Cancer ; 9(5)2021 05.
Article in En | MEDLINE | ID: mdl-33980590
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma / Biomarkers, Tumor / Promoter Regions, Genetic / Urologic Neoplasms / Telomerase / Urothelium / Immune Checkpoint Inhibitors / Mutation Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Language: En Journal: J Immunother Cancer Year: 2021 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma / Biomarkers, Tumor / Promoter Regions, Genetic / Urologic Neoplasms / Telomerase / Urothelium / Immune Checkpoint Inhibitors / Mutation Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male Language: En Journal: J Immunother Cancer Year: 2021 Document type: Article Affiliation country: Country of publication: